{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T21:28:19Z","timestamp":1749072499388},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00105-020-04612-4","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T12:02:53Z","timestamp":1590667373000},"page":"588-596","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aktinische Keratosen"],"prefix":"10.1007","volume":"71","author":[{"given":"M. V.","family":"Heppt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Steeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.-M.","family":"Szeimies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Berking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"4612_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2340\/00015555-2692","volume":"97","author":"R Cerio","year":"2017","unstructured":"Cerio\u00a0R, Dirschka\u00a0T, Dreno\u00a0B et\u00a0al (2017) Actinic keratosis, a\u00a0chronic, progressive disease: understanding clinical gaps to optimise patient management. Acta Derm Venereol 97:997\u2013998","journal-title":"Acta Derm Venereol"},{"key":"4612_CR2","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.24284","volume":"115","author":"VD Criscione","year":"2009","unstructured":"Criscione\u00a0VD, Weinstock\u00a0MA, Naylor\u00a0MF et\u00a0al (2009) Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical Tretinoin Chemoprevention trial. Cancer 115:2523\u20132530","journal-title":"Cancer"},{"key":"4612_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","volume":"28","author":"T Dirschka","year":"2017","unstructured":"Dirschka\u00a0T, Gupta\u00a0G, Micali\u00a0G et al (2017) Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J\u00a0Dermatolog Treat 28:431\u2013442","journal-title":"J Dermatolog Treat"},{"key":"4612_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jdv.12848","volume":"29","author":"MT Fernandez-Figueras","year":"2015","unstructured":"Fernandez-Figueras\u00a0MT, Carrato\u00a0C, Saenz\u00a0X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J\u00a0Eur Acad Dermatol Venereol 29:991\u2013997","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdv.14652","volume":"32","author":"I Figueras Nart","year":"2018","unstructured":"Figueras Nart\u00a0I, Cerio\u00a0R, Dirschka\u00a0T et\u00a0al (2018) Defining the actinic keratosis field: a\u00a0literature review and discussion. J\u00a0Eur Acad Dermatol Venereol 32:544\u2013563","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000366525","volume":"46","author":"AC Green","year":"2015","unstructured":"Green\u00a0AC (2015) Epidemiology of actinic keratoses. Curr Probl Dermatol 46:1\u20137","journal-title":"Curr Probl Dermatol"},{"key":"4612_CR7","first-page":"275","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt\u00a0MV, Leiter\u00a0U, Steeb\u00a0T et al (2020) S3-Leitlinie \u201eAktinische Keratose und Plattenepithelkarzinom der Haut\u201c \u2013 Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitatsindikatoren. J\u00a0Dtsch Dermatol Ges 18:275\u2013294","journal-title":"J Dtsch Dermatol Ges"},{"key":"4612_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jdv.15459","volume":"33","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Leiter\u00a0U et al (2019) Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a\u00a0meta-analysis. J\u00a0Eur Acad Dermatol Venereol 33:863\u2013873","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.17435","volume":"180","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Ruzicka\u00a0T et al (2019) Cryosurgery combined with topical interventions for actinic keratosis: a\u00a0systematic review and meta-analysis. Br J Dermatol 180:740\u2013748","journal-title":"Br J Dermatol"},{"key":"4612_CR10","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/picato. Zugegriffen: 25.02.2020"},{"key":"4612_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2012.03.048","volume":"149","author":"B Hu","year":"2012","unstructured":"Hu\u00a0B, Castillo\u00a0E, Harewood\u00a0L et\u00a0al (2012) Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 149:1207\u20131220","journal-title":"Cell"},{"key":"4612_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archdermatol.2012.1060","volume":"148","author":"M Huerta-Brogeras","year":"2012","unstructured":"Huerta-Brogeras\u00a0M, Olmos\u00a0O, Borbujo\u00a0J et al (2012) Validation of dermoscopy as a\u00a0real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol 148:1159\u20131164","journal-title":"Arch Dermatol"},{"key":"4612_CR13","doi-asserted-by":"publisher","unstructured":"Jansen MHE, Kessels J, Merks I et al (2020) A trial-based cost-effectiveness analysis of topical 5\u2011fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.18884","DOI":"10.1111\/bjd.18884"},{"key":"4612_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen\u00a0MHE, Kessels\u00a0J, Nelemans\u00a0PJ et\u00a0al (2019) Randomized trial of four treatment approaches for actinic keratosis. N\u00a0Engl J Med 380:935\u2013946","journal-title":"N Engl J Med"},{"key":"4612_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jdv.15422","volume":"33","author":"S Karrer","year":"2019","unstructured":"Karrer\u00a0S, Aschoff\u00a0RAG, Dominicus\u00a0R et al (2019) Methyl aminolevulinate daylight photodynamic therapy applied at home for non-hyperkeratotic actinic keratosis of the face or scalp: an open, interventional study conducted in Germany. J\u00a0Eur Acad Dermatol Venereol 33:661\u2013666","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/bjd.14355","volume":"174","author":"A Lallas","year":"2016","unstructured":"Lallas\u00a0A, Tschandl\u00a0P, Kyrgidis\u00a0A et\u00a0al (2016) Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis. Br J Dermatol 174:1079\u20131085","journal-title":"Br J Dermatol"},{"key":"4612_CR17","first-page":"400","volume":"18","author":"U Leiter","year":"2020","unstructured":"Leiter\u00a0U, Heppt\u00a0MV, Steeb\u00a0T et al (2020) S3-Leitlinie \u201eAktinische Keratose und Plattenepithelkarzinom der Haut\u201c \u2013 Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Pravention und Berufskrankheit. J\u00a0Dtsch Dermatol Ges 18:400\u2013413","journal-title":"J Dtsch Dermatol Ges"},{"key":"4612_CR18","first-page":"691","volume":"57","author":"A Marinescu","year":"2016","unstructured":"Marinescu\u00a0A, Stepan\u00a0AE, Margaritescu\u00a0C et\u00a0al (2016) P53, p16 and Ki67 immunoexpression in cutaneous squamous cell carcinoma and its precursor lesions. Rom J Morphol Embryol 57:691\u2013696","journal-title":"Rom J Morphol Embryol"},{"key":"4612_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","volume":"1","author":"R Marks","year":"1988","unstructured":"Marks\u00a0R, Rennie\u00a0G, Selwood\u00a0TS (1988) Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1:795\u2013797","journal-title":"Lancet"},{"key":"4612_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1067\/mjd.2000.103343","volume":"42","author":"RL Moy","year":"2000","unstructured":"Moy\u00a0RL (2000) Clinical presentation of actinic keratoses and squamous cell carcinoma. J\u00a0Am Acad Dermatol 42:8\u201310","journal-title":"J Am Acad Dermatol"},{"key":"4612_CR21","first-page":"335","volume":"16","author":"PJ Quaedvlieg","year":"2006","unstructured":"Quaedvlieg\u00a0PJ, Tirsi\u00a0E, Thissen\u00a0MR et\u00a0al (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335\u2013339","journal-title":"Eur J Dermatol"},{"key":"4612_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1067\/mjd.2000.103342","volume":"42","author":"SJ Salasche","year":"2000","unstructured":"Salasche\u00a0SJ (2000) Epidemiology of actinic keratoses and squamous cell carcinoma. J\u00a0Am Acad Dermatol 42:4\u20137","journal-title":"J Am Acad Dermatol"},{"key":"4612_CR23","doi-asserted-by":"publisher","unstructured":"Salido-Vallejo R, Jimenez-Najar F, Garnacho-Sucedo G et al (2019) Combined daylight and conventional photodynamic therapy with 5\u2011aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a\u00a0new and efficient approach. Arch Dermatol Res. https:\/\/doi.org\/10.1007\/s00403-019-02028-2","DOI":"10.1007\/s00403-019-02028-2"},{"key":"4612_CR24","first-page":"803","volume":"12","author":"I Schafer","year":"2014","unstructured":"Schafer\u00a0I, Reusch\u00a0M, Siebert\u00a0J et al (2014) Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. J\u00a0Dtsch Dermatol Ges 12:803\u2013811","journal-title":"J Dtsch Dermatol Ges"},{"key":"4612_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2133.2010.10118.x","volume":"164","author":"J Schmitt","year":"2011","unstructured":"Schmitt\u00a0J, Seidler\u00a0A, Diepgen\u00a0TL et al (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a\u00a0systematic review and meta-analysis. Br J Dermatol 164:291\u2013307","journal-title":"Br J Dermatol"},{"key":"4612_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/jdv.14512","volume":"32","author":"L Schmitz","year":"2018","unstructured":"Schmitz\u00a0L, Gambichler\u00a0T, Gupta\u00a0G et\u00a0al (2018) Actinic keratoses show variable histological basal growth patterns\u2014a\u00a0proposed classification adjustment. J\u00a0Eur Acad Dermatol Venereol 32:745\u2013751","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/jdv.13626","volume":"30","author":"L Schmitz","year":"2016","unstructured":"Schmitz\u00a0L, Kahl\u00a0P, Majores\u00a0M et\u00a0al (2016) Actinic keratosis: correlation between clinical and histological classification systems. J\u00a0Eur Acad Dermatol Venereol 30:1303\u20131307","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4612_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaad.2019.09.037","volume":"82","author":"T Steeb","year":"2020","unstructured":"Steeb\u00a0T, Niesert\u00a0AC, French\u00a0LE et al (2020) Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a\u00a0systematic review and meta-analysis. J\u00a0Am Acad Dermatol 82:515\u2013519","journal-title":"J Am Acad Dermatol"},{"key":"4612_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaad.2018.09.021","volume":"80","author":"T Steeb","year":"2019","unstructured":"Steeb\u00a0T, Schlager\u00a0JG, Kohl\u00a0C et al (2019) Laser-assisted photodynamic therapy for actinic keratosis: a systematic review and meta-analysis. J\u00a0Am Acad Dermatol 80:947\u2013956","journal-title":"J Am Acad Dermatol"},{"key":"4612_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00105-014-2759-6","volume":"65","author":"T Strunk","year":"2014","unstructured":"Strunk\u00a0T, Szeimies\u00a0RM (2014) Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options. Hautarzt 65:241\u2013252 (quiz 253\u2013244)","journal-title":"Hautarzt"},{"key":"4612_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner\u00a0RN, Sammain\u00a0A, Erdmann\u00a0R et\u00a0al (2013) The natural history of actinic keratosis: a\u00a0systematic review. Br J Dermatol 169:502\u2013518","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04612-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04612-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04612-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T10:45:30Z","timestamp":1666694730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04612-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4612"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04612-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.V.\u00a0Heppt hat Vortrags- und Beraterhonorare von Galderma, Almirall Hermal und Sanofi erhalten. T.\u00a0Steeb gibt an, dass kein Interessenskonflikt besteht. R.-M.\u00a0Szeimies hat als Pr\u00fcfarzt an klinischen Studien im Indikationsgebiet der Firmen Almirall, Biofrontera, Galderma und Leo Pharma teilgenommen, von den genannten Firmen sowie photonamic Vortrags- und Beraterhonorare erhalten und ist Mitglied in Advisory Boards von Almirall, Beiersdorf, Biofrontera, Galderma, Leo Pharma und photonamic. Er war ferner an der Entwicklung eines ALA-haltigen transdermalen therapeutischen Systems (TTS) und einer LED-Lampe zur PDT beteiligt. C.\u00a0Berking hat Beraterhonorare von Almirall Hermal, Galderma, Leo Pharma und Sanofi-Aventis sowie Vortragshonorare von Leo Pharma erhalten. C.\u00a0Berking hat als Pr\u00fcf\u00e4rztin an klinischen Studien im Indikationsgebiet Aktinische Keratosen der Firma Biofrontera teilgenommen. Dar\u00fcber hinaus hat C.\u00a0Berking von Leo Pharma finanzielle Mittel f\u00fcr klinische Forschung erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}